Profile of olaparib in the treatment of advanced ovarian cancer

Dana M Chase1,2, Shreya Patel2,3, Kristin Shields4
1Division of Gynecologic Oncology, The University of Arizona Cancer Center, 2Division of Gynecologic Oncology, 3Creighton University School of Medicine, St Joseph’s Hospital and Medical Center, Phoenix, AZ, 4Department of Trauma, Critical Care, and Acute Care Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

Abstract: Olaparib is a poly(ADP-ribose) polymerase inhibitor that received accelerated approval from the US Food and Drug Administration as monotherapy for patients with germline BRCA mutations and ovarian cancer treated with three or more prior lines of chemotherapy. This article summarizes the mechanism of poly(ADP-ribose) polymerase inhibition, therapeutic profile and uses of olaparib, and current and ongoing literature pertaining to olaparib in advanced ovarian cancer.

Keywords: olaparib, PARP, ovarian cancer

Introduction
Olaparib (AZD-2281, trade name Lynparza) is a poly(ADP-ribose) polymerase (PARP) inhibitor approved by US Food and Drug Administration (FDA) as monotherapy for ovarian cancer patients with germline BRCA mutations who have been treated with three or more prior lines of chemotherapy. The FDA concurrently approved the BRACAnalysis CDx™ (Myriad Genetics) as a companion diagnostic test. The BRACAnalysis CDx™ tests for deleterious or suspected deleterious variants in BRCA1/2 using whole blood specimens. PARP1/2 enzymes repair single-stranded DNA breaks through base excision repair. Unrepaired single-stranded breaks are converted into double-stranded breaks when cells attempt replication or transcription. Double-stranded breaks are normally repaired with homologous recombination. However, up to 50% of high-grade serous ovarian cancers lack homologous recombination through a combination of germline mutations in BRCA1/2; silencing via methylation of the, eg, BRCA promoter or Fanconi F; activation of pathway inhibitors; or other mechanisms.1 This leaves cells dependent on nonhomologous end joining, an error-prone repair method that leads to genetic instability and cell death. BRCA1/2 are homologous repair proteins; therefore, cells with BRCA1/2 mutations are specifically targeted by PARP inhibition. PARP inhibitors also trap PARP1 and 2 enzymes on DNA, leading to complexing, which interferes with DNA replication and causes further cellular damage.2 This article reviews the pharmacologic and safety profile of olaparib as well as the effects of BRCA mutations and platinum sensitivity on efficacy and the ongoing research in the use of olaparib for advanced ovarian cancer.

Pharmacokinetics, dose response, and safety
Olaparib is a rapidly absorbed orally active agent with peak plasma levels attained at 1–3 hours after administration and a mean terminal half-life of 11.9 hours. Phase I pharmacokinetic and pharmacodynamic testing of olaparib in 60 patients with solid tumors, including 21 ovarian cancer patients, established a maximum tolerated dose...
Table 1 Major study results and toxicities

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA mutation, recurrent HGSOC, platinum sensitive (97)</td>
<td>BRCA mutation, recurrent HGSOC, sensitive (65)</td>
<td>+/- BRCA, recurrent HGSOC, platinum resistant (193)</td>
<td>+/- BRCA, recurrent HGSOC, platinum sensitive (162)</td>
<td>+/- BRCA, recurrent HGSOC, platinum sensitive (265)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olaparib dose</td>
<td>400 mg bid, 200 mg bid</td>
<td>400 mg bid, 100 mg bid</td>
<td>400 mg bid</td>
<td>200 mg bid with chemo, 400 mg bid maintenance</td>
<td>400 mg bid maintenance</td>
<td></td>
</tr>
<tr>
<td>Toxicities (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>200 mg</td>
<td>400 mg</td>
<td>200 mg</td>
<td>400 mg</td>
<td>200 mg</td>
<td>400 mg</td>
</tr>
<tr>
<td>Vomiting</td>
<td>37</td>
<td>48</td>
<td>39</td>
<td>200 mg</td>
<td>50</td>
<td>68.4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>12</td>
<td>15</td>
<td>0</td>
<td>50</td>
<td>15</td>
<td>31.6</td>
</tr>
<tr>
<td>Anorexia</td>
<td>30</td>
<td>33</td>
<td>0</td>
<td>12</td>
<td>29</td>
<td>22.8</td>
</tr>
<tr>
<td>Fatigue</td>
<td>21</td>
<td>25</td>
<td>21</td>
<td>15</td>
<td>17</td>
<td>48.5</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>8</td>
<td>14</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>13</td>
<td>16</td>
<td>NA</td>
<td>8</td>
<td>32.1</td>
<td>16.2</td>
</tr>
<tr>
<td>Anemia</td>
<td>12</td>
<td>14</td>
<td>12</td>
<td>14</td>
<td>16</td>
<td>16.9</td>
</tr>
<tr>
<td>Outcome</td>
<td>PFS 6.5 mo (200 mg), 16.6 mo (PLD)</td>
<td>ORR 33% in 400 mg bid and 13% in 100 mg bid groups</td>
<td>ORR 29% (41% in BRCA mutated, 24% WT)</td>
<td>PFS 7 mo, OS</td>
<td>PFS 12.2 mo in olaparib plus chemo group versus 9.6 mo in placebo group</td>
<td>PFS 8.4 mo in olaparib group versus 4.8 mo in placebo group</td>
</tr>
</tbody>
</table>

Abbreviations: HGSOC, high-grade serous ovarian cancer; PFS, progression-free survival; mo, month; PLD, pegylated liposomal doxorubicin; ORR, objective response rate; OS, overall survival; TRR, tumor response rate; WT, wild type; NA, no data.
clinically significant. Feeding also increased the rate of absorption.\textsuperscript{7}

**Efficacy in patients without BRCA mutations**

Olaparib has also demonstrated efficacy in patients without BRCA mutations. Gelmon et al conducted a multicenter, nonrandomized Phase II study that included 63 women with advanced high-grade serous ovarian cancer. The patients were treated with olaparib 400 mg twice daily. The ORR was 41\% (seven of 17, 95\% CI 22–64) for patients with BRCA 1/2 mutations and 24\% (eleven of 46, 95\% CI 14–38) for patients without BRCA 1/2 mutations. In this study, patients with platinum-sensitive disease had ORR 50\% in the BRCA 1/2 mutation negative cohort versus 60\% in the cohort with mutation. This contrasted with the platinum-resistant population, where the ORR was 33\% in patients with BRCA 1/2 mutation and 4\% in the BRCA 1/2 mutation negative cohort.\textsuperscript{8}

**Efficacy of olaparib in platinum-sensitive and platinum-resistant diseases**

Maintenance therapy in platinum-sensitive patients improved progression-free survival in comparison to placebo in a randomized, double blind, Phase II trial by Ledermann et al. Two hundred and sixty-five patients with recurrent ovarian cancer who had at least two prior courses of platinum-based chemotherapy and an objective response to the most recent regimen were randomized to olaparib 400 mg twice daily or matching placebo until progression. The progression-free survival was 8.4 months with olaparib compared to 4.8 months with placebo (hazard ratio [HR] 0.35, 95\% CI 0.25–0.49; \textit{P}<0.001). The patient’s quality of life, as measured by Functional Assessment of Cancer Therapy – Ovarian (FACT-O) and variables derived from the FACT-O, was not different between olaparib and placebo groups. Most patients reported a best treatment outcome index as “improved” or “no change” during treatment, supporting the conclusion that there was no negative impact on the patient’s quality of life during treatment.\textsuperscript{9}

Efficacy in platinum resistance was investigated in a multicenter Phase II trial by Kaufman et al. A study population of 298 patients with platinum-resistant cancers and a germline BRCA 1/2 mutation (including 193 patients with ovarian, primary peritoneal, or fallopian tube cancers) was administered olaparib 400 mg twice daily until disease progression. These patients had a mean of 4.3 prior regimens. The tumor response rate was 26.2\% overall (95\% CI 21.3–31.6), and the response rate for ovarian cancer patients was 31.1\% (95\% CI 24.6–38.1). The median duration of response was 225 days, and the median progression-free survival was 7 months.\textsuperscript{10}

**Olaparib in combination with chemotherapy**

It has been proposed that olaparib could potentiate the effect of DNA-damaging chemotherapy. Oza et al conducted a randomized, open-label, Phase II study of 162 patients with recurrent, platinum-sensitive, high-grade serous ovarian cancers who had received up to three prior regimens of platinum-based chemotherapy. Patients received olaparib 200 mg twice daily plus paclitaxel 165 mg/m\textsuperscript{2} and carboplatin AUC4 followed by olaparib 400 mg twice daily maintenance versus carboplatin and paclitaxel alone. Patients in the olaparib plus chemotherapy group had a longer progression-free survival (12.2 versus 9.6 months for chemotherapy alone, HR 0.51, 95\% CI 0.34–0.77; \textit{P}=0.0012). This benefit was more pronounced in patients with known BRCA mutation (HR 0.21, 95\% CI 0.08–0.55; \textit{P}=0.0015).\textsuperscript{11}

The addition of antiangiogenic agents to olaparib has also been studied. An open-label comparison of olaparib 400 mg twice daily or olaparib 200 mg twice daily with cediranib 30 mg daily in patients with recurrent, high-grade, platinum-sensitive serous ovarian cancer or BRCA-related ovarian cancer evaluated 90 patients, stratified by BRCA status. Progression-free survival was 17.7 months in the group receiving cediranib versus 9 months in the olaparib-only group. (HR 0.42, 95\% CI 0.23–0.76; \textit{P}=0.005). However, toxicity was higher in the combination group than in the olaparib-alone group (27\% versus 11\% fatigue, 41\% versus 0\% hypertension, and 23\% versus 0\% diarrhea), and 75\% of the combination group required dose reduction.\textsuperscript{12} A small Phase I study investigated increasing doses of olaparib in combination with bevacizumab 10 mg/kg every 2 weeks. Adverse events were generally mild, and the most frequent events were fatigue and nausea. Significant adverse events (small bowel obstruction with perforation) were attributed to bevacizumab, rather than olaparib.\textsuperscript{13}

**Efficacy in recurrent ovarian cancer compared to pegylated liposomal doxorubicin**

An open-label, randomized trial of women with ovarian, primary peritoneal, or fallopian tube cancers that recurred or progressed within 12 months of the most recent platinum-based chemotherapy investigated olaparib at 200–400 mg
twice daily versus intravenous pegylated liposomal doxorubicin (PLD) 50 mg/m² every 28 days. The trial enrolled 97 patients and allowed crossover from PLD group to 400 mg olaparib group in the event of disease progression. In the 200 mg olaparib, 400 mg olaparib, and PLD groups, the median progression-free survival was 6.5 months (95% CI 5.5–10.1), 8.8 months (95% CI 5.4–9.2), and 7.1 months (95% CI 3.7–10.7 months), respectively. The ORRs were 25%, 31%, and 18%, respectively. There was no statistically significant difference between the olaparib or PLD groups in terms of either progression-free survival or ORR. Grade 3 to 4 treatment associated adverse events were more common in the PLD group. Improvement in the patient’s quality of life as measured by FACT-O was significantly increased in the olaparib group versus the PLD group (odds ratio 7.23, 95% CI 1.09–143.3; \( P=0.039 \)).

Long-term safety and efficacy

Van der Noll et al collected data on the long-term safety and efficacy of olaparib in a Phase I cohort of 21 patients who had received olaparib in combination with carboplatin and/or paclitaxel. Patients continued olaparib monotherapy (400 mg bid) after the Phase I combination study if they had completed six or more cycles of combination therapy, had no evidence of disease progression, and had significant toxicity from the combination therapy. Bone marrow suppression, fatigue, pain, and nausea decreased over time after combination therapy was discontinued. Gastrointestinal toxicities, such as gastritis, esophagitis, and dyspepsia, increased in frequency with longer duration use of olaparib, but were reduced with proton pump inhibitors. Response to therapy was diurnal, with the median duration of treatment 52 weeks. The best overall response was 43% complete response, 22% partial response, 29% stable disease, 5% progressive disease, and 5% not evaluable.

Ongoing research

SOLO-1 and SOLO-2 are multicenter, double-blind studies of olaparib 300 mg bid versus placebo in patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. Both SOLO-1 and SOLO-2 have primary outcomes of progression-free survival by response evaluation criteria in solid tumors (RECIST) criteria in olaparib 300 mg twice daily monotherapy maintenance compared to placebo. The study population of SOLO-1 is BRCA-mutated high-risk advanced ovarian cancer patients who achieved complete or partial response with first-line platinum chemotherapy, whereas the population of SOLO-2 is BRCA-mutated relapsed ovarian cancer patients who achieved complete or partial response with platinum chemotherapy. In SOLO-1, the patients will receive olaparib versus placebo for up to 2 years or until objective response by RECIST criteria and the treatment may continue beyond 2 years for those with stable disease or progression. Patients in SOLO-2 will receive olaparib versus placebo until progression by RECIST criteria or as long as they are benefiting from treatment and do not meet other criteria for discontinuation.

The current FDA approval for olaparib is for patients who have received three or more prior lines of chemotherapy. A recent study by Marques et al investigated whether the administration of chemotherapy affected intratumoral PARP expression. Tissue samples were obtained from three cohorts, totaling 313 high-grade serous ovarian cancers. PARP1 expression was measured by immunohistochemistry and Western blot protein analysis. Samples from patients who had undergone chemotherapy had significantly lower protein expression than chemotherapy-naïve tumor samples. Of 15 samples from patients which had both pre- and postchemotherapy (carboplatin and paclitaxel), six had absent PARP1 expression and eight had reduced PARP1 levels postchemotherapy. The clinical significance of this change in PARP1 expression is unknown; however, the dynamic interaction of PARP1 and chemotherapy should be taken into consideration in future studies. It is possible that the use of olaparib before exposure to multiple lines of chemotherapy would be a more effective use.

Conclusion

Olaparib is a well-tolerated oral chemotherapeutic agent that has FDA approval for the treatment of ovarian cancer in patients with germline BRCA 1/2 mutations who have received three or more prior lines of chemotherapy. In the future, development of assays for function of homologous recombination may help to identify patients without a germline BRCA 1/2 mutation who would also benefit from treatment with olaparib. Further studies will also help delineate the optimal timing and setting of olaparib administration.

Disclosure

The authors report no conflicts of interest in this work.

References


International Journal of Women’s Health

Publish your work in this journal

The International Journal of Women’s Health is an international, peer-reviewed open-access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of women’s healthcare including gynecology, obstetrics, and breast cancer. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.